Endovascular implantation of 125I seed combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma. (May 2018)

• Record Type: Journal Article
• Authors: Sun, Houbin; Zhang, Minghui; Liu, Ruibao; Liu, Yan; Hou, Yingwen; Wu, Changjun
• Is Part Of: Future oncology. Volume 14:Number 12(2018)
• Page Start: 1165
• Page End: 1176
• Publication Date: 2018-05
• Subjects: 125I seed -- hepatocellular carcinoma -- portal vein tumor thrombosis -- TACE; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2017-0354
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: The purpose of this study was to evaluate the efficacy and safety of the endovascular implantation of 125 I seed under ultrasound and x-ray guidance combined with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).Patients & methods: The study included 134 pathologically proven or clinically confirmed primary HCC patients with PVTT in our hospital from January 2013 to June 2015.Results & conclusion: Compared with the TACE treatment alone, the combination therapy of 125 I seed implantation with TACE significantly prolonged the median survival time and improved the 6-, 12- and 18-month survival rates for HCC patients with PVTT. In addition, the type III PVTT and tumor size were independent predictors for poor prognosis of HCC patients with PVTT.